Rammensee, Hans-Georg <br/><br/>
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.  [electronic resource] 

 -  Journal for immunotherapy of cancer  11 2019 
 - 307 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2051-1426 
<br/><br/><label>Standard No.: </label>10.1186/s40425-019-0796-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--therapeutic use<br/>B-Lymphocytes--immunology<br/>CD4-Positive T-Lymphocytes--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Dendritic Cells--immunology<br/>Granuloma--immunology<br/>HEK293 Cells<br/>Healthy Volunteers<br/>Humans<br/>Killer Cells, Natural--immunology<br/>Ligands<br/>Male<br/>Middle Aged<br/>Peptides--therapeutic use<br/>Toll-Like Receptor 1--immunology<br/>Toll-Like Receptor 2--immunology<br/>Vaccination